A Phase 2 interventional study of Abemaciclib in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.
Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 35th largest by enrollment, is the only one that started in 2018, is one of 27 in phase 2, and was the 15th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Japanese Foundation for Cancer Research · Sites in Japan
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 29 · Phase 3 11 · Phase 4 8
First in 2014; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 55 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 55 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 57th largest by enrollment of the 80 interventional ones that give a count, is the only one that started in 2018, is one of 41 in phase 2, and was the 65th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
6 of the studies testing abemaciclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06341621Phase 3Fudan UniversityChemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib | 2027-02-25 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT06207734Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDiscontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | 2027-01-10 |
| NCT04614194University of Texas Southwestern Medical CenterSingle Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | 2027-04-15 |
| NCT04305834City of Hope Medical CenterAbemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 55 studies testing abemaciclib in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have all of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 mg abemaciclib given twice a day (BID) orally with a meal.
Drug: Abemaciclib
200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
Drug: Abemaciclib
200 mg abemaciclib given twice a day (BID) orally without regard for food.
Drug: Abemaciclib
Administered orally.
Also known as: LY2835219
Percentage of Participants With Severe Diarrhea (≥ Grade 3)
Percentage of participants with severe diarrhea (≥ grade 3) during the first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 was defined as an increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care activities of daily living (ADL).
Time frame: Cycle 3 (28 Days Cycle)
Percentage of Participants With Prolonged Grade 2 Diarrhea
Percentage of participants with prolonged grade 2 diarrhea during first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Prolonged Grade 2 diarrhea was any event lasting more than 7 days. Grade 2 was defined as Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline.
Time frame: Cycle 3 (28 Days Cycle)
Percentage of Participants With Dose Reductions Due to Diarrhea
Percentage of participants with dose reductions due to diarrhea during first 3 cycles.
Time frame: Cycle 3 (28 Days Cycle)
Percentage of Participants With Dose Interruptions Due to Diarrhea
Percentage of participants with dose interruptions due to diarrhea during first 3 cycles.
Time frame: Cycle 3 (28 Days Cycle)
Percentage of Participants Who Discontinue Treatment Due to Diarrhea
Percentage of participants who discontinue treatment due to diarrhea
Time frame: Cycle 3 (28 Days Cycle)
Percentage of Participants Utilizing Antidiarrheals
Percentage of participants who utilized anti diarrheals at least once during the first 3 cycles.
Time frame: Cycle 3 (28 Days Cycle)
Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib
PK: Mean steady state exposure of abemaciclib
Time frame: Cycle 1: Day 15; Cycle 2: Day 1, Day 15; Cycle 3: Day 1 (28 Days Cycle)
PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567
PK: Mean steady state exposure of abemaciclib metabolite LSN2839567
Time frame: Cycle 1: Day 15; Cycle 2: Day1, Day 15; Cycle 3: Day 1 (28 Days Cycle)
PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726
PK: Mean steady state exposure of abemaciclib metabolite LSN3106726
Time frame: Cycle 1: Day 15; Cycle 2: Day1, Day 15; Cycle 3: Day 1 (28 Days Cycle)
| Milestone | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Started | 24 | 24 | 24 |
| Received at least one dose of study drug | 24 | 23 | 24 |
| Completed | 20 | 18 | 22 |
| Not completed | 4 | 6 | 2 |
| Withdrew: Death | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 |
| Withdrew: Completed < 3 cycles | 2 | 2 | 2 |
Percentage of participants with severe diarrhea (≥ grade 3) during the first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 was defined as an increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care activities of daily living (ADL).
| percentage of participants | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Percentage of Participants With Severe Diarrhea (≥ Grade 3) | 4.2 | 0 | 0 |
Percentage of participants with prolonged grade 2 diarrhea during first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Prolonged Grade 2 diarrhea was any event lasting more than 7 days. Grade 2 was defined as Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline.
| percentage of participants | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Percentage of Participants With Prolonged Grade 2 Diarrhea | 8.3 | 17.4 | 20.8 |
Percentage of participants with dose reductions due to diarrhea during first 3 cycles.
| percentage of participants | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Percentage of Participants With Dose Reductions Due to Diarrhea | 16.7 | 8.7 | 12.5 |
Percentage of participants with dose interruptions due to diarrhea during first 3 cycles.
| percentage of participants | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Percentage of Participants With Dose Interruptions Due to Diarrhea | 16.7 | 4.3 | 8.3 |
Percentage of participants who discontinue treatment due to diarrhea
| percentage of participants | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Percentage of Participants Who Discontinue Treatment Due to Diarrhea | 0 | 0 | 0 |
Percentage of participants who utilized anti diarrheals at least once during the first 3 cycles.
| percentage of participants | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Percentage of Participants Utilizing Antidiarrheals | 95.8 | 91.3 | 95.8 |
PK: Mean steady state exposure of abemaciclib
| nanogram/milliliter (ng/mL) | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Cycle 1: Day 15 | 305 ± 198 | 369 ± 64 | 356 ± 75 |
| Cycle 2: Day 1 | 320 ± 91 | 280 ± 99 | 190 ± 284 |
| Cycle 2: Day 15 | 77.4 ± 731 | 345 ± 51 | 223 ± 250 |
| Cycle 3: Day 1 | 135 ± 896 | 330 ± 54 | 85.4 ± 498 |
PK: Mean steady state exposure of abemaciclib metabolite LSN2839567
| nanogram/milliliter (ng/mL) | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Cycle 1 Day 15 | 139 ± 109 | 129 ± 48 | 159 ± 61 |
| Cycle 2 Day 1 | 125 ± 62 | 109 ± 84 | 96.3 ± 127 |
| Cycle 2 Day 15 | 50.4 ± 276 | 121 ± 45 | 112 ± 79 |
| Cycle 3 Day 1 | 89.4 ± 110 | 125 ± 48 | 61.7 ± 122 |
PK: Mean steady state exposure of abemaciclib metabolite LSN3106726
| nanogram/milliliter (ng/mL) | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| Cycle 1 Day 15 | 231 ± 120 | 242 ± 38 | 287 ± 63 |
| Cycle 2 Day 1 | 230 ± 59 | 210 ± 57 | 152 ± 222 |
| Cycle 2 Day 15 | 80.5 ± 377 | 221 ± 31 | 182 ± 112 |
| Cycle 3 Day 1 | 146 ± 174 | 223 ± 33 | 107 ± 172 |
Collected over Baseline until end of the follow-up (Up To 44 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg Abemaciclib With a Meal | 3/24 (12.5%) | 3/24 (12.5%) | 24/24 (100%) |
| 200 mg Abemaciclib Without a Meal | 4/23 (17.4%) | 5/23 (21.7%) | 23/23 (100%) |
| 200 mg Abemaciclib Without Regard to Food | 1/24 (4.2%) | 8/24 (33.3%) | 24/24 (100%) |
| Event | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| NauseaGastrointestinal disorders | 0/24 | 3/23 | 0/24 |
| VomitingGastrointestinal disorders | 1/24 | 2/23 | 0/24 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/24 | 0/23 | 2/24 |
| Hepatic function abnormalHepatobiliary disorders | 0/24 | 1/23 | 0/24 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/24 | 1/23 | 0/24 |
| Superficial vein thrombosisVascular disorders | 0/24 | 1/23 | 0/24 |
| AnaemiaBlood and lymphatic system disorders | 0/24 | 0/23 | 1/24 |
| Atrial fibrillationCardiac disorders | 0/24 | 0/23 | 1/24 |
| DiarrhoeaGastrointestinal disorders | 1/24 | 0/23 | 1/24 |
| PancreatitisGastrointestinal disorders | 0/24 | 0/23 | 1/24 |
| Event | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 21/24 | 22/23 | 22/24 |
| NauseaGastrointestinal disorders | 15/24 | 11/23 | 14/24 |
| AnaemiaBlood and lymphatic system disorders | 14/24 | 11/23 | 10/24 |
| FatigueGeneral disorders | 11/24 | 4/23 | 10/24 |
| Platelet count decreasedInvestigations | 11/24 | 7/23 | 5/24 |
| VomitingGastrointestinal disorders | 10/24 | 10/23 | 7/24 |
| Abdominal painGastrointestinal disorders | 10/24 | 4/23 | 5/24 |
| Neutrophil count decreasedInvestigations | 7/24 | 6/23 | 10/24 |
| NeutropeniaBlood and lymphatic system disorders | 6/24 | 8/23 | 9/24 |
| White blood cell count decreasedInvestigations | 9/24 | 7/23 | 7/24 |
All randomized participants.
| Age, Continuous(years) | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food | Total |
|---|---|---|---|---|
| Mean | 58.2 ± 11.6 | 56.9 ± 11.1 | 57.6 ± 8.3 | 57.6 ± 10.3 |
| Sex: Female, Male(Participants) | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food | Total |
|---|---|---|---|---|
| Female | 23 | 24 | 24 | 71 |
| Male | 1 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 24 | 19 | 20 | 63 |
| Unknown or Not Reported | 0 | 5 | 3 | 8 |
| Race (NIH/OMB)(Participants) | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 22 | 24 | 24 | 70 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 200 mg Abemaciclib With a Meal | 200 mg Abemaciclib Without a Meal | 200 mg Abemaciclib Without Regard to Food | Total |
|---|---|---|---|---|
| Turkey | 6 | 6 | 6 | 18 |
| Belgium | 0 | 1 | 0 | 1 |
| Australia | 11 | 10 | 10 | 31 |
| Spain | 6 | 6 | 7 | 19 |
| Russia | 1 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2018 to primary completion in Jul 2019, 8 months.
Results were first posted in Aug 2020, 1 year after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 8 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib